Table 1.

Clinical Trials of Bevacizumab for CNS Tumors

Study	Phase	Number of patients	Presentation	Radiation technique	Radiation dose/fractions	Bevacizumab dose	Chemotherapy	Surgery	Median PFS (mo)	Median OS (mo)
Lai 2011	II	70	Newly diagnosed GBM	Conformal	60 Gy/30	10 mg/kg	Temozolamide	3% biopsy 57% subtotal resection 40% total resection	14.2	19.6
Narayana 2011	II	51	Newly diagnosed GBM	Conformal	59.4 Gy/33	10 mg/kg	Temozolamide	11% biopsy 18% subtotal resection 71% gross resection	13	23
Desjardins 2011	II	75	Newly diagnosed GBM	Conformal	59.4 Gy/33	10 mg/kg	Temozolamide and irinotecan	46% subtotal resection 53% gross resection	14.2	21.2
Gutin 2009	I	25	Recurrent GBM and anaplastic gliomas	Stereotactic	30 Gy/5	10 mg/kg	None	Only 2 patients with resection	7.3-7.5	12.5-16.5

Abbreviations: PFS, progression-free survival; OS, overall survival